Document is current
Any future updates will be listed below
-
Authors
Ríos, Israel
Schiaffino, María Teresa
López-Navarro, Baltasar
Triguero-Martínez, Ana
Lin, Marry
Torres-Torresano, Mónica
Struys, Eduard A.
Álvarez, Susana
Román, Manuel
Abad-Santos, Francisco
Castañeda, Santos
Garcia-Castañeda, Noelia
de Jonge, Robert
Jansen, Gerrit
Castrejón, Isabel
González-Álvaro, Isidoro
Puig-Kröger, Amaya https://orcid.org/0000-0003-2943-9757
-
Funding
Funding for this research was provided by:
Instituto de Salud Carlos III (PI20/00316)
Instituto de Salud Carlos III (PI23/00224)
Instituto de Salud Carlos III (RD21/0002/0034)
Instituto de Salud Carlos III (RD24/0007/0029)
Instituto de Salud Carlos III (PI20/00847)
Instituto de Salud Carlos III (PI23/01226)
Instituto de Salud Carlos III (RD21/0002/0027)
Instituto de Salud Carlos III (RD24/0007/0006)
Comunidad de Madrid (P2022/BMD-7274)
- License Information
-
More Information
Article History
Received: 19 September 2025
Revised: 8 January 2026
Accepted: 20 February 2026
First Online: 17 March 2026
Declarations
:
: The study was conducted in accordance with the Declaration of Helsinki, was approved by the AEMPS (August 05th 2019) and the Ethical Committee of Hospital Universitario La Princesa and Hospital General Universitario Gregorio Marañón (protocol code: METOMAC-PAC, IGA-MET-2019–01).
: IC reports consulting and/or speaker fees from Alfasigma, Boehringer, BMS, Eli-Lilly, Galapagos, Gebro Pharma, Gilead, GSK, Pfizer, UCB, not related to the submitted work. IGA reports personal fees from Lilly and Sanofi; personal fees and nonfinancial support from BMS; personal fees and non-financial support from Abbvie; research support, personal fees and non- financial support from Roche Laboratories; research support from Gebro Pharma; non-financial support from MSD, Pfizer and Novartis, not related to the submitted work. The other co-authors declare no potential conflicts of interest.
